ImmunityBio Inc. (IBRX)

ImmunityBio Inc. (IBRX $2.39)
- $2.39 Cap: $2.26B
- View IBRX Profile
- View Questions on IBRX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

ImmunityBio Inc. (IBRX $2.39)
- $2.39 Cap: $2.26B
- View IBRX Profile
- View Questions on IBRX

Q: Is ibrx a reasonable company to make a small investment in?
Its treatment anktiva is approved for some cancers already and appears to have broader applications. The patents seem to have about 10 years to run.
Thank you for your research and opinion.

Read Answer Asked by maida on December 02, 2025

Crinetics Pharmaceuticals Inc. (CRNX $50.52)
- $50.52 Cap: $4.54B
- View CRNX Profile
- View Questions on CRNX
Scholar Rock Holding Corporation (SRRK $47.36)
- $47.36 Cap: $4.55B
- View SRRK Profile
- View Questions on SRRK
ImmunityBio Inc. (IBRX $2.39)
- $2.39 Cap: $2.26B
- View IBRX Profile
- View Questions on IBRX

Q: Hello 5i Team,

Your thoughts on these 3 names. SRRK & CRNX gave us good returns with the recent run and I intend to replace with IBRX.

Thank you!

Read Answer Asked by Nhung on October 31, 2024